Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
_↗ news.bms.com
News Image

A definitive agreement has been announced by Bristol Myers Squibb(BMS) to acquire Orbital Therapeutics for $1.5 billion in cash, a move designed to significantly strengthen and diversify BMS's industry-leading cell therapy portfolio by pioneering a new generation of RNA medicines. (BMS) to acquire Orbital Therapeutics for $1.5 billion in cash, a move designed to significantly strengthen and diversify BMS's industry-leading cell therapy portfolio by pioneering a new generation of RNA medicines. for $1.5 billion in cash, a move designed to significantly strengthen and diversify BMS's industry-leading cell therapy portfolio by pioneering a new generation of RNA medicines. (BMS) to acquire Orbital Therapeutics for $1.5 billion in cash, a move designed to significantly strengthen and diversify BMS's industry-leading cell therapy portfolio by pioneering a new generation of RNA medicines.

Orbital is a privately held biotechnology company focused on reprogramming the immune system in vivo to treat diseases, with a particular focus on autoimmune conditions.

The centerpiece of the acquisition is OTX-201, Orbital’s lead preclinical candidate currently in IND-enabling studies. OTX-201 is an investigational next-generation CAR T-cell therapy that uses an optimized circular RNA encoding a CD19-targeted CAR, delivered via targeted lipid nanoparticles (LNPs), for in vivo expression. This innovative in vivo approach allows the patient's own body to manufacture the CAR T-cells, potentially offering a reduced treatment burden and improved accessibility compared to the complex ex vivo CAR T-cell therapies currently available.

BMS’s Chief Research Officer, Dr. Robert Plenge, noted that this approach could redefine the treatment of autoimmune diseases by depleting autoreactive B cells and resetting the immune system. The deal also includes Orbital’s proprietary RNA platform, which integrates circular and linear RNA engineering, advanced LNP delivery, and AI-driven design, enabling the creation of durable, programmable RNA therapies for a broad spectrum of diseases beyond autoimmune indications. BMS, already a leader with two approved CAR T-cell therapies, views the acquisition of Orbital’s platform as a critical step in making CAR T-cell therapy more efficient and accessible to more patients globally.

Log In
Sign Up